ScholarIQanswers from OpenAlex & ORCID
Constance Cirrincione
ResearcherPublications, citations & collaboration network
Constance Cirrincione is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Constance Cirrincione have?
ScholarIQindexed works
Constance Cirrincione has 118 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Constance Cirrincione have?
ScholarIQcitation count
Constance Cirrincione has 16,649 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Constance Cirrincione?
ScholarIQh-index
Constance Cirrincione has an h-index of 45 in OpenAlex.
What is the i10-index of Constance Cirrincione?
ScholarIQi10-index
Constance Cirrincione has an i10-index of 71 in OpenAlex.
What is the OpenAlex record for Constance Cirrincione?
ScholarIQopenalex
The OpenAlex for Constance Cirrincione is on the source record.
What are the most-cited papers on Constance Cirrincione?
ScholarIQmost cited works
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron, Donald A. Berry, Constance Cirrincione, Clifford A. Hudis, Eric P. Winer, William J. Gradishar, Nancy E. Davidson, Silvana Martino, Robert B. Livingston, James N. Ingle, Edith A. Perez, John T. Carpenter, David D. Hurd, James F. Holland, Barbara L. Smith, Carolyn I. Sartor, Eleanor H. Leung, Jeffrey S. Abrams, Richard L. Schilsky, Hyman B. Muss, Larry Norton
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Kevin S. Hughes, Lauren A. Schnaper, Jennifer R. Bellon, Constance Cirrincione, Donald A. Berry, Beryl McCormick, Hyman B. Muss, Barbara L. Smith, Clifford A. Hudis, Eric P. Winer, William C. Wood
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
Kevin S. Hughes, Lauren A. Schnaper, Donald A. Berry, Constance Cirrincione, Beryl McCormick, Brenda Shank, Judith Wheeler, Lorraine A. A. Champion, Thomas J. Smith, Barbara L. Smith, Charles M. Shapiro, Hyman B. Muss, Eric P. Winer, Clifford A. Hudis, William Wood, David J. Sugarbaker, I. Craig Henderson, Larry Norton
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance Cirrincione, Sara M. Tolaney, Charles Kuzma, Timothy Pluard, George Somlo, Elisa Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey, Donald A. Berry, Constance Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay N. Harris, David W. Ollila, Ian E. Krop, N. Lynn Henry, Douglas Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael D. Iglesia, Maggie C.U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis